By Christy Santhosh Feb 23 (Reuters) - Gilead Sciences will pay as much as $7.8 billion to acquire partner Arcellx in its ...
Policymakers should prepare now for the likelihood that the decision will in some degree at least open the door to challenges to all health care provided only through speech. State licensing boards ...
For many women in the United States who encounter drenching night sweats, sudden hot flashes, debilitating exhaustion and other menopausal symptoms, small estradiol patches worn on the skin have ...
UCLA researchers use lipid nanoparticles to insert full CFTR gene into airway cells, restoring function and opening new ...
Psychotherapy evolves within broader cultural and intellectual traditions, continually reinterpreting enduring human questions.
Discover how TMS therapy targets depression at the source. A deep dive into the physics, safety protocols, and FDA-cleared ...
With $55 billion earmarked to bolster its U.S. operations, Johnson & Johnson is the latest drugmaker to zero in on expansion ...
Boehringer Ingelheim is discarding an inhaled gene therapy designed to treat cystic fibrosis (CF) after terminating a phase 1/2 trial. | Boehringer Ingelheim is discarding an inhaled gene therapy ...
A growing body of research shows that getting outside is good for mood and memory. Some therapists are bringing their ...
It will provide strategies for productive aging. Participants will learn about home safety, modifications, fall prevention ...
Feb 23 (Reuters) - Gilead Sciences said on Monday it will buy cancer therapy partner Arcellx for an implied equity value of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results